Selectivity of µ-opioid receptor determined by interfacial residues near third extracellular loop

European Journal of Pharmacology

Volumn 403, Issue 1-2, 2000, Pages 37-44

  Bonner, Gregg ^a   Meng, Fan ^a   Akil, Huda ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

(35S)GTP S; Ligand selectivity; Mutagenesis; Opioid receptor

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; BREMAZOCINE; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LIGAND; LYSINE; MORPHINE; MU OPIATE RECEPTOR; MUTANT PROTEIN; NALOXONAZINE; NALOXONE; NALTREXONE; NALTRINDOLE; OPIATE AGONIST; TRYPTOPHAN;

AMINO ACID COMPOSITION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL STRAIN COS1; DRUG RECEPTOR BINDING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR AFFINITY;

AMINO ACID SUBSTITUTION; ANIMALS; BENZAMIDES; BENZOMORPHANS; BINDING SITES; BINDING, COMPETITIVE; COS CELLS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, D-PENICILLAMINE (2,5)-; FENTANYL; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LIGANDS; MORPHINE; MUTATION; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PEPTIDES; PIPERAZINES; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; SULFUR RADIOISOTOPES;

EID: 0034284055     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00578-1     Document Type: Article

References (20)

1. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein coupled receptors. Methods Neurosci. 25:1995;366-428.
2. 35S)GTPγS binding: a tool to evaluate functional activity of a cloned opioid receptor transiently expressed in COS cells. Neurochem. Res. 21:1996;1301-1307.
3. Bunzow J.R., Saez C., Mortrud M., Bouvier C., Williams J.T., Low M., Grandy D.K. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene that is not μ, δ, or κ opioid receptor type. FEBS Lett. 347:1994;284-288.
4. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:1987;745-2752.
5. Deng W.P., Nickoloff I.A. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem. 200:1991;81-88.
6. 6 glioma cell line expressing the μ opioid receptor. J. Pharmacol. Exp. Ther. 278:1996;1121-1127.
7. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21:2000;90-113.
8. Goldstein A., Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol. Pharmacol. 36:1989;265-272.
9. Hjorth S.A., Thirstrup K., Grandy D.K., Schwartz T.W. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine. Mol. Pharmacol. 47:1995;1089-1094.
10. Huggenvik J.I., Collard M.W., Stofko R.E., Seasholtz A.F., Uhler M.D. Regulation of the human enkephalin promoter by two isoforms of the catalytic subunit of cyclic adenosine 3′,5′-monophosphate-dependent protein kinase. Mol. Endocrinol. 5:1991;921-930.
11. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U. S. A. 89:1992;12048-12052.
12. Meng F., Xie G.-X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;9954-9958.
13. Meng F., Taylor L.P., Hoversten M.T., Ueda Y., Ardati A., Reinscheid R.K., Monsma F.J., Watson S.J., Civelli O., Akil H. Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J. Biol. Chem. 271:1996;32016-32020.
14. Onogi T., Minami M., Katao Y., Nakagawa T., Aoki Y., Toya T., Katsumata S., Satoh M. DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ and δ-opioid receptors around their first extracellular loops. FEBS Lett. 357:1995;93-97.
15. Pogozheva I.D., Lomize A.L., Mosberg H.I. Opioid three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys. J. 75:1998;612-634.
16. Seki T., Minami M., Nakagawa T., Ienaga Y., Morisada A., Satoh M. DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors. Eur. J. Pharmacol. 350:1998;301-310.
17. Thompson R.C., Mansour A., Akil H., Watson S.J. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron. 11:1993;903-913.
18. Valiquette M., Vu H.K., Yue S.Y., Wahlestedt C., Walker P. Involvement of Trp-284, Val-296, and Val-297 of the human delta-opioid receptor in binding of delta-selective ligands. J. Biol. Chem. 271:1996;18789-18796.
19. Varga E.V., Li X., Stropova D., Zalewska T., Landsman R.S., Knapp R.J., Malatynska E., Kawai K., Mizusura A., Nagase H., Calderon S.N., Rice K., Hruby V.J., Roeske W.R., Yamamura H.I. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists. Mol. Pharmacol. 50:1996;1619-1624.
20. 319 of the rat mu-opioid receptor in binding of mu-selective ligands. Synapse. 32:1999;23-28.